Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia: a randomized, double-blind, placebo-controlled, phase II trial
Background: Patients with cognitive impairment associated with schizophrenia may benefit from treatments targeting dysfunctional glutamatergic neurotransmission. BI 409306, a potent and selective phosphodiesterase 9 inhibitor, was assessed in patients with schizophrenia using a learn-and-confirm ada...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2019
|
| In: |
Schizophrenia bulletin
Year: 2018, Jahrgang: 45, Heft: 2, Pages: 350-359 |
| ISSN: | 1745-1701 |
| DOI: | 10.1093/schbul/sby049 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1093/schbul/sby049 Verlag, Volltext: https://academic.oup.com/schizophreniabulletin/article/45/2/350/4990640 
|
| Verfasserangaben: | David Brown, Kazuyuki Nakagome, Joachim Cordes, Ronald Brenner, Gerhard Gründer, Richard S.E. Keefe, Robert Riesenberg, David P. Walling, Kristen Daniels, Lara Wang, Jennifer McGinniss, and Michael Sand |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1665831057 | ||
| 003 | DE-627 | ||
| 005 | 20220816153822.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190516r20192018xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/schbul/sby049 |2 doi | |
| 035 | |a (DE-627)1665831057 | ||
| 035 | |a (DE-599)KXP1665831057 | ||
| 035 | |a (OCoLC)1341224705 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Brown, David |e VerfasserIn |0 (DE-588)1186306017 |0 (DE-627)1665829737 |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia |b a randomized, double-blind, placebo-controlled, phase II trial |c David Brown, Kazuyuki Nakagome, Joachim Cordes, Ronald Brenner, Gerhard Gründer, Richard S.E. Keefe, Robert Riesenberg, David P. Walling, Kristen Daniels, Lara Wang, Jennifer McGinniss, and Michael Sand |
| 264 | 1 | |c 2019 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.05.2019 | ||
| 500 | |a Advance Access publication 1 May 2018 | ||
| 520 | |a Background: Patients with cognitive impairment associated with schizophrenia may benefit from treatments targeting dysfunctional glutamatergic neurotransmission. BI 409306, a potent and selective phosphodiesterase 9 inhibitor, was assessed in patients with schizophrenia using a learn-and-confirm adaptive trial design. Methods: This double-blind, parallel-group trial randomized patients 2:1:1:1:1 to once-daily placebo or BI 409306 (10, 25, 50, or 100 mg) for 12 weeks. Stage 1 (learn) assessed change from baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) scores (week 12) to identify ≥1 meaningful endpoints for stage 2 (confirm). If no domains showed efficacy, change from baseline in Measurements and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) composite scores (week 12) was the primary endpoint. The key secondary endpoint was change from baseline in Schizophrenia Cognition Rating Scale (SCoRS) total score. Safety was monitored. Results: Five hundred eighteen patients were randomized. In stage 1, CANTAB did not differentiate between BI 409306 and placebo (n = 120), so the primary endpoint of change from baseline in MCCB composite score was analyzed in 450 patients in stage 2. There was no significant difference between BI 409306 (1.2-2.8) and placebo (2.5) in MCCB composite score change. BI 409306 did not significantly improve change from baseline in SCoRS total score (-3.1 to -2.0) vs placebo (-2.5). Adverse events were dose-dependent, increasing from 33.3% (10 mg) to 53.5% (100 mg), vs 36.4% for placebo. Conclusion: The primary endpoint of cognitive function improvement was not met. BI 409306 was well-tolerated, with an acceptable safety profile. | ||
| 534 | |c 2018 | ||
| 700 | 1 | |a Gründer, Gerhard |e VerfasserIn |0 (DE-588)1078251037 |0 (DE-627)838195350 |0 (DE-576)449927644 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Schizophrenia bulletin |d Oxford : Oxford Univ. Press, 1969 |g 45(2019), 2, Seite 350-359 |h Online-Ressource |w (DE-627)481280243 |w (DE-600)2180196-4 |w (DE-576)261040812 |x 1745-1701 |7 nnas |a Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia a randomized, double-blind, placebo-controlled, phase II trial |
| 773 | 1 | 8 | |g volume:45 |g year:2019 |g number:2 |g pages:350-359 |g extent:10 |a Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia a randomized, double-blind, placebo-controlled, phase II trial |
| 856 | 4 | 0 | |u https://doi.org/10.1093/schbul/sby049 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/schizophreniabulletin/article/45/2/350/4990640 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190516 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1078251037 |a Gründer, Gerhard |m 1078251037:Gründer, Gerhard |d 60000 |e 60000PG1078251037 |k 0/60000/ |p 5 | ||
| 999 | |a KXP-PPN1665831057 |e 3476592456 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"note":["Gesehen am 09.01.14"],"disp":"Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia a randomized, double-blind, placebo-controlled, phase II trialSchizophrenia bulletin","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["481280243"],"zdb":["2180196-4"],"issn":["1745-1701"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisher":"Oxford Univ. Press","dateIssuedDisp":"1969-","dateIssuedKey":"1969","publisherPlace":"Oxford"}],"recId":"481280243","name":{"displayForm":["US Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health"]},"pubHistory":["1.1969 -"],"part":{"volume":"45","text":"45(2019), 2, Seite 350-359","year":"2019","issue":"2","pages":"350-359","extent":"10"},"language":["eng"],"title":[{"title":"Schizophrenia bulletin","title_sort":"Schizophrenia bulletin"}]}],"note":["Gesehen am 16.05.2019","Advance Access publication 1 May 2018"],"physDesc":[{"extent":"10 S."}],"id":{"doi":["10.1093/schbul/sby049"],"eki":["1665831057"]},"recId":"1665831057","origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"2019"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"display":"Brown, David","role":"aut","given":"David","family":"Brown"},{"family":"Gründer","display":"Gründer, Gerhard","role":"aut","given":"Gerhard"}],"name":{"displayForm":["David Brown, Kazuyuki Nakagome, Joachim Cordes, Ronald Brenner, Gerhard Gründer, Richard S.E. Keefe, Robert Riesenberg, David P. Walling, Kristen Daniels, Lara Wang, Jennifer McGinniss, and Michael Sand"]},"language":["eng"],"title":[{"title_sort":"Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia","title":"Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia","subtitle":"a randomized, double-blind, placebo-controlled, phase II trial"}]} | ||
| SRT | |a BROWNDAVIDEVALUATION2019 | ||